Alumis Inc Dossier
Qualitative Analysis
Business overview
Alumis Inc. (NASDAQ: ALMS) is a clinical-stage biopharmaceutical company focused on developing oral therapies using a precision medicine approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. The company's strategic centerpiece is envudeucitinib (formerly ESK-001), a next-generation, highly selective, oral allosteric inhibitor of tyrosine kinase 2 (TYK2) designed to correct immune dysregulation across a range of diseases driven by proinflammatory mediators. Alumis is also developing A-005, a first-in-class central nervous system (CNS)-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, and has historically explored subcutaneous anti-IGF-1R therapies like lonigutamab.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead oral TYK2 inhibitor envudeucitinib through late-stage clinical trials, including the Phase 3 ONWARD program for moderate-to-severe plaque psoriasis and the Phase 2b LUMUS trial for systemic lupus erythematosus, while preparing for regulatory NDA submission.
Expected impact: Establish envudeucitinib as a best-in-class oral therapy for plaque psoriasis and other immune-mediated diseases.
Exploring strategic alternatives, including potential out-licensing or partnership opportunities, for lonigutamab (an anti-IGF-1R antibody for thyroid eye disease acquired in the ACELYRIN merger) rather than advancing the asset internally into Phase 3 trials.
Expected impact: Preserves capital and extends cash runway by avoiding up to $100.5 million in development/regulatory milestones and $390 million in commercial milestones.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
All-stock merger to create a combined immunology-focused biopharmaceutical company, expanding the pipeline with lonigutamab (thyroid eye disease) and significantly strengthening the pro forma cash position to extend the operating runway into 2027.
Financial impact: Significantly increased cash balances (pro forma cash of ~$737 million at announcement) and extended the combined company's cash runway into late 2027.
Strategic Partnerships
Secures regional development and commercialization rights for envudeucitinib (ESK-001) in dermatology indications in Japan, leveraging Kaken's regional expertise.
Terms: Alumis received a $20.0 million upfront license payment in 2025, with eligibility for future development, regulatory, and commercial milestones up to $140.0 million, plus tiered royalties on net sales.